المؤلفون: Markus Berger (216106), Lars Wortmann (6190562), Philipp Buchgraber (2063245), Ulrich Lücking (2614105), Sabine Zitzmann-Kolbe (340479), Antje M. Wengner (8769686), Benjamin Bader (2982786), Ulf Bömer (8283762), Hans Briem (1788724), Knut Eis (6190565), Hartmut Rehwinkel (4508851), Florian Bartels (8190036), Dieter Moosmayer (1399678), Uwe Eberspächer (8900651), Philip Lienau (2614111), Stefanie Hammer (222697), Christoph A. Schatz (11327011), Qiuwen Wang (1584481), Qi Wang (22418), Dominik Mumberg (167909), Carl F. Nising (2706721), Gerhard Siemeister (2614108)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Genetics, Molecular Biology, Pharmacology, Immunology, Cancer, Hematology, Space Science, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, G 2 cell cycle phase, Shows Synergistic Efficacy, PSMA-targeted thorium -227 conjugat., Rad 3-related protein, BAY -8400, prostate tumor-bearing mice, DNA-dependent protein kinase, Targeted Alpha Therapies Eukaryotes, ATR, Combination, DNA double-strand breaks, inhibitor, Selective DNA-PK Inhibitor

Relation: https://figshare.com/articles/journal_contribution/BAY-8400_A_Novel_Potent_and_Selective_DNA-PK_Inhibitor_which_Shows_Synergistic_Efficacy_in_Combination_with_Targeted_Alpha_Therapies/16434808

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00762.s001

المؤلفون: Ulrich Lücking (2614105), Dirk Kosemund (8769683), Niels Böhnke (11139232), Philip Lienau (2614111), Gerhard Siemeister (2614108), Karsten Denner (7422248), Rolf Bohlmann (2685706), Hans Briem (1788724), Ildiko Terebesi (11139235), Ulf Bömer (8283762), Martina Schäfer (2397241), Stuart Ince (11139238), Dominik Mumberg (167909), Arne Scholz (11139241), Raquel Izumi (3151191), Stuart Hwang (11139244), Franz von Nussbaum (3022791)

مصطلحات موضوعية: Medicine, Cell Biology, Pharmacology, Immunology, Cancer, Hematology, Infectious Diseases, Chemical Sciences not elsewhere classified, candidate VIP 152, Selective CDK 9 Inhibitor VIP 152, Weekly Intravenous Dosing, CDK 9 inhibitor, VIP 152, B-cell lymphoma patients, CDK 9 inhibitors, underexplored benzyl sulfoximine group

Relation: https://figshare.com/articles/journal_contribution/Changing_for_the_Better_Discovery_of_the_Highly_Potent_and_Selective_CDK9_Inhibitor_VIP152_Suitable_for_Once_Weekly_Intravenous_Dosing_for_the_Treatment_of_Cancer/14988016

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01000.s002

المؤلفون: Markus Berger (216106), Lars Wortmann (6190562), Philipp Buchgraber (2063245), Ulrich Lücking (2614105), Sabine Zitzmann-Kolbe (340479), Antje M. Wengner (8769686), Benjamin Bader (2982786), Ulf Bömer (8283762), Hans Briem (1788724), Knut Eis (6190565), Hartmut Rehwinkel (4508851), Florian Bartels (8190036), Dieter Moosmayer (1399678), Uwe Eberspächer (8900651), Philip Lienau (2614111), Stefanie Hammer (222697), Christoph A. Schatz (11327011), Qiuwen Wang (1584481), Qi Wang (22418), Dominik Mumberg (167909), Carl F. Nising (2706721), Gerhard Siemeister (2614108)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Genetics, Molecular Biology, Pharmacology, Immunology, Cancer, Hematology, Space Science, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, G 2 cell cycle phase, Shows Synergistic Efficacy, PSMA-targeted thorium -227 conjugat., Rad 3-related protein, BAY -8400, prostate tumor-bearing mice, DNA-dependent protein kinase, Targeted Alpha Therapies Eukaryotes, ATR, Combination, DNA double-strand breaks, inhibitor, Selective DNA-PK Inhibitor

Relation: https://figshare.com/articles/dataset/BAY-8400_A_Novel_Potent_and_Selective_DNA-PK_Inhibitor_which_Shows_Synergistic_Efficacy_in_Combination_with_Targeted_Alpha_Therapies/16434811

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00762.s002

المؤلفون: Ulrich Lücking (2614105), Dirk Kosemund (8769683), Niels Böhnke (11139232), Philip Lienau (2614111), Gerhard Siemeister (2614108), Karsten Denner (7422248), Rolf Bohlmann (2685706), Hans Briem (1788724), Ildiko Terebesi (11139235), Ulf Bömer (8283762), Martina Schäfer (2397241), Stuart Ince (11139238), Dominik Mumberg (167909), Arne Scholz (11139241), Raquel Izumi (3151191), Stuart Hwang (11139244), Franz von Nussbaum (3022791)

مصطلحات موضوعية: Medicine, Cell Biology, Pharmacology, Immunology, Cancer, Hematology, Infectious Diseases, Chemical Sciences not elsewhere classified, candidate VIP 152, Selective CDK 9 Inhibitor VIP 152, Weekly Intravenous Dosing, CDK 9 inhibitor, VIP 152, B-cell lymphoma patients, CDK 9 inhibitors, underexplored benzyl sulfoximine group

Relation: https://figshare.com/articles/dataset/Changing_for_the_Better_Discovery_of_the_Highly_Potent_and_Selective_CDK9_Inhibitor_VIP152_Suitable_for_Once_Weekly_Intravenous_Dosing_for_the_Treatment_of_Cancer/14988013

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01000.s001